1231 related articles for article (PubMed ID: 19244107)
21. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal.
Chan SC; Li Y; Dehm SM
J Biol Chem; 2012 Jun; 287(23):19736-49. PubMed ID: 22532567
[TBL] [Abstract][Full Text] [Related]
22. Androgen-dependent regulation of Her-2/neu in prostate cancer cells.
Berger R; Lin DI; Nieto M; Sicinska E; Garraway LA; Adams H; Signoretti S; Hahn WC; Loda M
Cancer Res; 2006 Jun; 66(11):5723-8. PubMed ID: 16740710
[TBL] [Abstract][Full Text] [Related]
23. Androgen receptor and invasion in prostate cancer.
Hara T; Miyazaki H; Lee A; Tran CP; Reiter RE
Cancer Res; 2008 Feb; 68(4):1128-35. PubMed ID: 18281488
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
Agoulnik IU; Weigel NL
J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
[TBL] [Abstract][Full Text] [Related]
25. Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.
Recouvreux MV; Wu JB; Gao AC; Zonis S; Chesnokova V; Bhowmick N; Chung LW; Melmed S
Endocrinology; 2017 Jul; 158(7):2255-2268. PubMed ID: 28444169
[TBL] [Abstract][Full Text] [Related]
26. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
27. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.
Huang KC; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
Cancer Biol Ther; 2014 Sep; 15(9):1120-8. PubMed ID: 24972028
[TBL] [Abstract][Full Text] [Related]
28. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.
Dehm SM; Schmidt LJ; Heemers HV; Vessella RL; Tindall DJ
Cancer Res; 2008 Jul; 68(13):5469-77. PubMed ID: 18593950
[TBL] [Abstract][Full Text] [Related]
29. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression.
Li Y; Hwang TH; Oseth LA; Hauge A; Vessella RL; Schmechel SC; Hirsch B; Beckman KB; Silverstein KA; Dehm SM
Oncogene; 2012 Nov; 31(45):4759-67. PubMed ID: 22266865
[TBL] [Abstract][Full Text] [Related]
30. Hormone depletion-insensitivity of prostate cancer cells is supported by the AR without binding to classical response elements.
Gonit M; Zhang J; Salazar Md; Cui H; Shatnawi A; Trumbly R; Ratnam M
Mol Endocrinol; 2011 Apr; 25(4):621-34. PubMed ID: 21330406
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Li Y; Chan SC; Brand LJ; Hwang TH; Silverstein KA; Dehm SM
Cancer Res; 2013 Jan; 73(2):483-9. PubMed ID: 23117885
[TBL] [Abstract][Full Text] [Related]
32. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades.
Huang Y; Feng G; Cai J; Peng Q; Yang Z; Yan C; Yang L; Wang Z
Life Sci; 2020 May; 248():117449. PubMed ID: 32088212
[TBL] [Abstract][Full Text] [Related]
33. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells.
Dehm SM; Tindall DJ
J Biol Chem; 2006 Sep; 281(38):27882-93. PubMed ID: 16870607
[TBL] [Abstract][Full Text] [Related]
34. The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer.
Clark EL; Coulson A; Dalgliesh C; Rajan P; Nicol SM; Fleming S; Heer R; Gaughan L; Leung HY; Elliott DJ; Fuller-Pace FV; Robson CN
Cancer Res; 2008 Oct; 68(19):7938-46. PubMed ID: 18829551
[TBL] [Abstract][Full Text] [Related]
35. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
Wang LG; Ossowski L; Ferrari AC
Cancer Res; 2001 Oct; 61(20):7544-51. PubMed ID: 11606392
[TBL] [Abstract][Full Text] [Related]
36. Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.
Marques RB; Dits NF; Erkens-Schulze S; van Ijcken WF; van Weerden WM; Jenster G
PLoS One; 2011; 6(8):e23144. PubMed ID: 21829708
[TBL] [Abstract][Full Text] [Related]
37. A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling.
Köhler A; Demir U; Kickstein E; Krauss S; Aigner J; Aranda-Orgillés B; Karagiannidis AI; Achmüller C; Bu H; Wunderlich A; Schweiger MR; Schaefer G; Schweiger S; Klocker H; Schneider R
Mol Cancer; 2014 Jun; 13():146. PubMed ID: 24913494
[TBL] [Abstract][Full Text] [Related]
38. Cyclin D3 action in androgen receptor regulation and prostate cancer.
Olshavsky NA; Groh EM; Comstock CE; Morey LM; Wang Y; Revelo MP; Burd C; Meller J; Knudsen KE
Oncogene; 2008 May; 27(22):3111-21. PubMed ID: 18084330
[TBL] [Abstract][Full Text] [Related]
39. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
Shen T; Wang W; Zhou W; Coleman I; Cai Q; Dong B; Ittmann MM; Creighton CJ; Bian Y; Meng Y; Rowley DR; Nelson PS; Moore DD; Yang F
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586682
[TBL] [Abstract][Full Text] [Related]
40. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
